See interview with OKYO CEO Gary Jacob. OKYO Pharma achieves key stability milestone for Urcosimod in clinical development. Thank you @proactive_UK Proactive USA $OKYO youtu.be/19GOXEOrVWs?si…

Great news today! OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain, Following the Early Closure of its Phase 2 Clinical Trial. $OKYO #ClinicalTrial #NCP #Pain #Phase2 okyopharma.com/okyo-pharma-an…

OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain OKYO Pharma LTD #NASDAQ #OKYO ow.ly/YPsj1067rii

Thank you Proactive USA for the interview with OKYO's CEO following todays announcement. See the full interview below. $OKYO youtu.be/H--dEJm0zio?si…

Big news today. FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain. $OKYO #FDA #FastTrack #Granted #NCP okyopharma.com/fda-grants-oky…

$OKYO FDA Grants Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit. OKYO CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on May 22. $OKYO Hanson Wade okyopharma.com/okyo-pharma-to…

OKYO Pharma to Present at the Bio International Convention next week! $OKYO #bio2025 #BIOBoston #Biotech Biotechnology Innovation Organization okyopharma.com/okyo-pharma-to…

$OKYO - Goldman Small Cap Research Issues New Research Update on OKYO Pharma, Raises target to $8 from $5 - stocktitan.net/news/OKYO/gold…

Goldman Research Provides Update Note on OKYO Pharma and Raises Price Target to $8. The Goldman update highlights that OKYO is the first company to launch and conclude a clinical trial in Neuropathic Corneal Pain (NCP) $OKYO okyopharma.com/investors/inve…

$OKYO OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts tinyurl.com/2a3yotok OKYO Pharma LTD #OKYO Proactive Proactive USA

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain. After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by

OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain OKYO Pharma LTD #NASDAQ #OKYO ow.ly/xjkc106fYbC

OKYO Pharma reports positive Phase 2 data in treating Neuropathic Corneal Pain OKYO Pharma LTD proactiveinvestors.com/companies/news… #proactiveinvestors #okyopharmalimited #nasdaq #okyo #Urcosimod

OKYO sets sights on first approval in neuropathic eye pain after phase 2 win. $OKYO FierceBiotech ftp.clinicaltrialrisk.com/biotech/okyo-s…

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain. $OKYO okyopharma.com/okyo-pharma-re…

Lucid Capital Markets have initiated coverage of OKYO Pharma with a Buy rating and a 12 month price target of $13. In a Phase 2 trial, after 12 weeks, 75% of patients with moderate to severe NCP saw over 80% pain reduction on urcosimod, with relief beginning as early as Week 4.

🗨️ “In my practice, where traditional therapies often fall short for this patient population, urcosimod could fill a long-standing therapeutic void,” Dr. Hardeep Kataria told Healio. More from OKYO Pharma LTD on the latest in neuropathic corneal pain. 👇 healio.com/news/optometry…

OKYO Pharma highlighted as #3 "Top 5 Small-cap Biotech Stocks of 2025" $OKYO nasdaq.com/articles/top-5…

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain. $OKYO okyopharma.com/okyo-pharma-an…